CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy

被引：47
|
作者：
Murad, Yanal M.
Clay, Timothy M.
Lyerly, H. Kim
Morse, Michael A.
机构：
[1] Duke Univ, Med Ctr, Program Mol Therapeut, Ctr Comprehens Canc,Dept Surg, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Program Mol Therapeut, Duke Comprehens Canc Ctr,Dept Pathol & Immunol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Program Mol Therapeut, Comprehens Canc Ctr,Dept Med, Durham, NC 27710 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 08期
关键词：
adjuvant; CPG-7909; PF-3512676; ProMune; TLR9;
D O I：
10.1517/14712598.7.8.1257
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleoticles (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune((R))) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.
引用
收藏
页码：1257 / 1266
页数：10
相关论文
共 50 条
  • [11] Clinical development of Toll-like receptor-9 agonists
    Schetter, Christian
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2007, 57 (01): : 75 - 75
  • [12] Toll-like receptor-9 ligands in tumor models
    Endres, Stefan
    Schreiber, Susanne
    Beck, Sebastian
    Hartmann, Gunther
    Bourquin, Carole
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2007, 57 (01): : 64 - 65
  • [13] Toll-Like Receptor 9 Activation with CpG Oligodeoxynucleotides for Asthma Therapy
    Kline, Joel N.
    Krieg, Arthur M.
    DRUG NEWS & PERSPECTIVES, 2008, 21 (08) : 434 - 439
  • [14] Silencing Toll-like receptor-9 in Pseudomonas aeruginosa keratitis
    Huang, X
    Barrett, RP
    McClellan, SA
    Hazlett, LD
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (11) : 4209 - 4216
  • [15] Systemic toll-like receptor 9 agonist CpG oligodeoxynucleotides exacerbates aminoglycoside ototoxicity
    Yang, Chao-Hui
    Hwang, Chung-Feng
    Chuang, Jiin-Haur
    Lian, Wei-Shiung
    Wang, Feng-Sheng
    Yang, Ming-Yu
    HEARING RESEARCH, 2021, 411
  • [16] Preliminary report on a phase I/II study of intraturnoral injection of PF-3512676 (CpG 7909), a TLR9 agonist, combined with radiation in recurrent low-grade lymphomas.
    Ai, Wei Yon Z.
    Kim, Youn
    Hoppe, Richard T.
    Shah, Sumit
    Horning, Sandra J.
    Tibshirani, Robert
    Levy, Ronald
    BLOOD, 2006, 108 (11) : 767A - 768A
  • [17] Interferon-beta and Toll-Like Receptor-9 Processing
    Zahednasab, Hamid
    Bahreini, Seyed Amir
    ANNALS OF NEUROLOGY, 2011, 69 (04) : 740 - 741
  • [18] Toll-Like Receptor-9 Expression Is Inversely Correlated with Estrogen Receptor Status in Breast Cancer
    Jukkola-Vuorinen, Arja
    Rahko, Eeva
    Vuopala, Katri S.
    Desmond, Renee
    Lehenkari, Petri P.
    Harris, Kevin W.
    Selander, Katri S.
    JOURNAL OF INNATE IMMUNITY, 2009, 1 (01) : 59 - 68
  • [19] Toll-Like Receptor 9 Agonists for Cancer Therapy
    Melisi, Davide
    Frizziero, Melissa
    Tamburrino, Anna
    Zanotto, Marco
    Carbone, Carmine
    Piro, Geny
    Tortora, Giampaolo
    BIOMEDICINES, 2014, 2 (03) : 211 - 228
  • [20] Regulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer
    Luo, Yun
    Jiang, Qi-Wei
    Wu, Jie-Ying
    Qiu, Jian-Ge
    Zhang, Wen-Ji
    Mei, Xiao-Long
    Shi, Zhi
    Di, Jin-Ming
    ONCOTARGET, 2015, 6 (26) : 22564 - 22574
12345